Menu
Mr. Zakes serves as Longevity Biomedical’s President and CEO. From 2009 to 2015, Mr. Zakes served as Founder, President, and CEO of Cerevast Medical, Inc. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent 30+ years in various segments of the pharmaceutical, biotechnology and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline) and ICOS Corporation.
While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac and Serevent. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University and an MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors and Executive Committee for the Biotechnology Innovation Organization (BIO) and serves as the organization’s Treasurer.
Prior to joining Longevity Biomedical, Ms. Sparks was the Controller at Resonant, Inc., a publicly traded company designing front-end radio frequency filters from 2020-2022. From 2016-2020 she was the Corporate Controller at Cancer Prevention Pharmaceuticals, Inc., a private clinical stage company developing treatments for cancer prevention. From 2015-2016 she was the Chief Accounting Officer at SynCardia Systems, Inc., a private company manufacturing the total artificial heart. From 2009-2015 she was the Controller/Division CFO for Myriad RBM, a division of Myriad Genetics, a publicly traded company developing genetic tests for cancer risk.
From 2007-2009 she was the Senior Director of Finance and Controller for ImaRx Therapeutics, Inc. a publicly traded biopharmaceutical company that develops and commercializes therapies for vascular disorders. At ImaRx she was responsible for all corporate accounting and finance functions. From 2004-2007, she was an independent consultant with numerous companies including Invitrogen
Dr. Curra is a recognized bioengineering executive with over 20 years of academic and private sector R&D experience in the fields of ultrasound imaging, high intensity focused ultrasound (HIFU), nonlinear acoustics, and tissue bioeffects. He has developed state-of-the-art 3D models for nonlinear propagation and HIFU therapy, innovative imaging transducers, and novel monitoring and feedback imaging protocols.
Dr. Curra primary R&D emphasis has been on the development of portable, point-of-care image-guided therapy systems for targeted clinical applications. He has made significant contributions to technology development in the areas of ultrasound-based cosmetic treatments and noninvasive and laparoscopic ultrasound surgery. Dr. Curra holds a Bachelor of Science in Bioengineering from Syracuse University and a Ph.D. in Bioengineering from the University of Washington. He is the inventor of several issued patents in medical ultrasound.
Mr. Leo is a seasoned executive with over 30 years of leadership experience in the biomedical industry. He has held key position at esteemed organizations such as Cerevast Medical, Sonus Pharmaceuticals, and Brigham and Women’s Hospital. Renowned for his expertise in regulatory affairs and quality management, Mr. Leo has been pivotal in driving operational excellence and aligning strategic goals with product innovation. Over the course of his career, he has successfully guided pharmaceutical, medical device, and biologic products from the startup phase through the commercial launch. Mr. Leo holds a Bachelor of Science degree in Chemistry from the University of Washington.
Longevity Biomedical, Inc
12100 NE 195th st. Suite 150
Bothell, WA 98011
+1 (425) 748-7529
info@longevitybiomedical.com
© 2022-2023 Longevity Biomedical Inc